• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Tomsche David Scott bought $15,554 worth of Common Stock $0.10 par value per share (3,266 units at $4.76), increasing direct ownership by 3% to 52,720 units (SEC Form 4)

    11/28/25 8:12:55 AM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ICCC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Tomsche David Scott

    (Last) (First) (Middle)
    C/O IMMUCELL CORPORATION
    56 EVERGREEN DRIVE

    (Street)
    PORTLAND ME 04103

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    IMMUCELL CORP /DE/ [ ICCC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    11/25/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock $0.10 par value per share 11/25/2025 P 1,633 A $4.76 52,720 D
    Common Stock $0.10 par value per share 11/25/2025 P 1,633 A $4.765 4,740 I By Spouse
    Common Stock $0.10 par value per share 73,927 I By David Tomsche Living Trust
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Timothy C. Fiori 11/28/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ICCC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ICCC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ICCC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: President and CEO Te Boekhorst Paul Francis Olivier bought $31,528 worth of Common Stock $0.10 par value per share (6,030 units at $5.23), increasing direct ownership by 163% to 9,738 units (SEC Form 4)

    4/A - IMMUCELL CORP /DE/ (0000811641) (Issuer)

    12/4/25 4:11:39 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Te Boekhorst Paul Francis Olivier bought $48,588 worth of Common Stock $0.10 par value per share (9,785 units at $4.97) (SEC Form 4)

    4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)

    12/3/25 4:14:14 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Tomsche David Scott bought $15,554 worth of Common Stock $0.10 par value per share (3,266 units at $4.76), increasing direct ownership by 3% to 52,720 units (SEC Form 4)

    4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)

    11/28/25 8:12:55 AM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ICCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025

    PORTLAND, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2025. Product Sales Highlights: During the third quarter of 2025, product sales decreased by 8% to approximately $5.5 million compared to the third quarter of 2024.During the nine-month period ended September 30, 2025, product sales increased by 7% to approximately $20.0 million compared to the nine-month per

    11/13/25 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025

    PORTLAND, Maine, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2025 after the market closes on Thursday, November 13, 2025. The Company is planning to host a conference call the next morning, Friday, November 14, 2025, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-

    11/6/25 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ImmuCell Announces Onboarding of New CEO and Related Management Changes

    PORTLAND, Maine, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the start date of its new CEO and related board changes. Effective November 1, 2025, Olivier te Boekhorst began serving as President and CEO of the Company, succeeding Michael F. Brigham. At its meeting on October 29, 2025, the Company's Board of Directors appointed Mr. te Boekhorst to the Board of Directors along with Timothy C. Fiori, CFO. Mr. Fiori joined ImmuCell as CFO in

    11/4/25 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ICCC
    SEC Filings

    View All

    SEC Form 10-Q filed by ImmuCell Corporation

    10-Q - IMMUCELL CORP /DE/ (0000811641) (Filer)

    11/13/25 4:08:17 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)

    11/13/25 4:07:40 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ImmuCell Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits, Results of Operations and Financial Condition

    8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)

    11/4/25 4:08:55 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ICCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: President and CEO Te Boekhorst Paul Francis Olivier bought $31,528 worth of Common Stock $0.10 par value per share (6,030 units at $5.23), increasing direct ownership by 163% to 9,738 units (SEC Form 4)

    4/A - IMMUCELL CORP /DE/ (0000811641) (Issuer)

    12/4/25 4:11:39 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Te Boekhorst Paul Francis Olivier bought $48,588 worth of Common Stock $0.10 par value per share (9,785 units at $4.97) (SEC Form 4)

    4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)

    12/3/25 4:14:14 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Tomsche David Scott bought $15,554 worth of Common Stock $0.10 par value per share (3,266 units at $4.76), increasing direct ownership by 3% to 52,720 units (SEC Form 4)

    4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)

    11/28/25 8:12:55 AM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ICCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by ImmuCell Corporation

    SC 13D - IMMUCELL CORP /DE/ (0000811641) (Subject)

    8/27/24 4:32:59 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13D/A filed by ImmuCell Corporation (Amendment)

    SC 13D/A - IMMUCELL CORP /DE/ (0000811641) (Subject)

    4/16/21 3:21:48 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - IMMUCELL CORP /DE/ (0000811641) (Subject)

    2/4/21 11:27:59 AM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ICCC
    Leadership Updates

    Live Leadership Updates

    View All

    ImmuCell Announces Selection of its Next President and CEO

    PORTLAND, Maine, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has selected Olivier te Boekhorst as its next President and CEO. The Company anticipates a start date of November 1, 2025 for Mr. te Boekhorst. Mr. te Boekhorst is currently an Operating Partner at ARCHIMED, a global investment firm focused on human and animal healthcare industries, and serves as Chair of the Board of SeqCenter, a Next Generation Sequencing laboratory

    9/29/25 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ImmuCell Hires Chief Financial Officer

    PORTLAND, Maine, April 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has hired Timothy C. Fiori to serve as its Chief Financial Officer. Mr. Fiori brings to ImmuCell approximately 24 years of finance and commercial operating experience with IDEXX Laboratories in Westbrook, Maine. He is a 2001 graduate of the University of Maine, Orono with a B.S in Finance. He lives in Raymond, Maine with his wife, Rachel, and enjoys many outdoor activ

    4/7/25 9:00:00 AM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ImmuCell Appoints Bryan K. Gathagan to Board of Directors

    PORTLAND, Maine, June 21, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that Bryan K. Gathagan has been appointed to its Board of Directors. Mr. Gathagan is the owner and a managing member of broad Thinking, LLC, a management consulting firm and has 25 years of animal health experience. He is a founding member of Animalytix LLC and has served as its Chief Financial and Chief Technology Officer since it began operations in 2010. Prior to Animalytix

    6/21/23 4:05:22 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ICCC
    Financials

    Live finance-specific insights

    View All

    ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025

    PORTLAND, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2025. Product Sales Highlights: During the third quarter of 2025, product sales decreased by 8% to approximately $5.5 million compared to the third quarter of 2024.During the nine-month period ended September 30, 2025, product sales increased by 7% to approximately $20.0 million compared to the nine-month per

    11/13/25 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025

    PORTLAND, Maine, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2025 after the market closes on Thursday, November 13, 2025. The Company is planning to host a conference call the next morning, Friday, November 14, 2025, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-

    11/6/25 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ImmuCell Announces Onboarding of New CEO and Related Management Changes

    PORTLAND, Maine, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the start date of its new CEO and related board changes. Effective November 1, 2025, Olivier te Boekhorst began serving as President and CEO of the Company, succeeding Michael F. Brigham. At its meeting on October 29, 2025, the Company's Board of Directors appointed Mr. te Boekhorst to the Board of Directors along with Timothy C. Fiori, CFO. Mr. Fiori joined ImmuCell as CFO in

    11/4/25 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care